Schedule 13G Filing by Vivo Opportunity Fund Holdings, L.P. for AN2 Therapeutics, Inc.

Vivo Opportunity Fund Holdings, L.P. and its related entities have filed a Schedule 13G, reporting beneficial ownership of 2,864,346 shares of AN2 Therapeutics, Inc. Common Stock, representing 8.0% of the outstanding shares. Vivo Opportunity, LLC, as the general partner, shares this beneficial ownership. Additionally, Vivo Opportunity Cayman Fund, L.P. holds 289,294 shares, representing 0.8% of the outstanding shares, with Vivo Opportunity Cayman, LLC as its general partner. These holdings were not acquired for the purpose of influencing or changing control of the issuer. The total number of outstanding shares is based on information available as of November 3, 2025, and shares issued in a private placement on March 10, 2026.